Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies

Neurologic Clinics

Volumn 34, Issue 1, 2016, Pages 17-31

  Moghadasi, Abdorreza Naser ^a   Pourmand, Shadi ^a   Sharifian, Maryam ^a   Minagar, Alireza ^b   Sahraian, Mohammad Ali ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Behavioral change; Cognition; Depression; Multiple sclerosis

Indexed keywords

DONEPEZIL; DULOXETINE; FLUVOXAMINE; MEMANTINE; NATALIZUMAB; PAROXETINE; PEGINTERFERON BETA1A; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AMNESIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; AUTOIMMUNE DISEASE; AUTOIMMUNE ENCEPHALOPATHY; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BLADDER DISEASE; BRAIN DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; DECISION MAKING; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EMOTIONAL INTELLIGENCE; EXECUTIVE FUNCTION; FATIGUE; GINKGO BILOBA; HUMAN; IMMUNOMODULATION; LONG TERM MEMORY; MEMORY DISORDER; MULTIPLE SCLEROSIS; ORTHOSTATIC HYPOTENSION; PARANEOPLASTIC NEUROPATHY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REHABILITATION; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; COGNITION DISORDERS; COMPLICATION; DISABLED PERSON; ENCEPHALITIS; HASHIMOTO DISEASE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; QUALITY OF LIFE;

COGNITION DISORDERS; DISABLED PERSONS; ENCEPHALITIS; HASHIMOTO DISEASE; HUMANS; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 84947997129     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2015.08.002     Document Type: Review

References (126)

1. Koch-Henriksen N., Sørensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9:520-532.
2. Patti F., Vila C. Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. Neuroepidemiology 2014, 42:211-218.
3. Calabrese P. Neuropsychology of multiple sclerosis: an overview. J Neurol 2006, 253(Suppl):10-15.
4. Jonsson A., Andresen J., Storr L., et al. Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. J Neurol Sci 2006, 245:77-85.
5. Amato M.P., Zipoli V., Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006, 245:41-46.
6. Longley W.A. Multiple sclerosis-related dementia: relatively rare and often misunderstood. Brain Impairment 2007, 8:154-167.
7. Schultheis M.T., Garay E., DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 2001, 56:1089-1094.
8. Rao S.M., Leo G.J., Ellington L., et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991, 41:692-696.
9. Rogers J.M., Panegyres P.K. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci 2007, 14:919-927.
10. Van Schependom J., D'hooghe M.B., Cleynhens K., et al. Reduced information processing speed as primum movens for cognitive decline in MS. Mult Scler 2015, 21:83-91.
11. Denney D.R., Gallagher K.S., Lynch S.G. Deficits in processing speed in patients with multiple sclerosis: evidence from explicit and covert measures. Arch Clin Neuropsychol 2011, 26:110-119.
12. Rao S.M., Martin A.L., Huelin R., et al. Correlations between MRI and information processing speed in MS: a meta-analysis. Mult Scler Int 2014, 2014:975803.
13. Bergendal G., Martola J., Stawiarz L., et al. Callosal atrophy in multiple sclerosis is related to cognitive speed. Acta Neurol Scand 2013, 127:281-289.
14. Chiaravalloti N.D., Stojanovic-Radic J., DeLuca J. The role of speed versus working memory in predicting learning new information in multiple sclerosis. J Clin Exp Neuropsychol 2013, 35:180-191.
15. Owens E.M., Denney D.R., Lynch S.G. Difficulties in planning among patients with multiple sclerosis: a relative consequence of deficits in information processing speed. J Int Neuropsychol Soc 2013, 19:613-620.
16. Niino M., Mifune N., Kohriyama T., et al. Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol 2014, 14:3.
17. Goretti B., Viterbo R.G., Portaccio E., et al. Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol Sci 2014, 35:559-563.
18. Labiano-Fontcuberta A., Mitchell A.J., Moreno-García S., et al. Anxiety and depressive symptoms in caregivers of multiple sclerosis patients: the role of information processing speed impairment. J Neurol Sci 2015, 349(1-2):220-225.
19. Hulst H.E., Schoonheim M.M., Van Geest Q., et al. Memory impairment in multiple sclerosis: relevance of hippocampal activation and hippocampal connectivity. Mult Scler 2015, [Epub ahead of print].
20. Brissart H., Leininger M., Le Perf M., et al. Working memory in multiple sclerosis: a review. Rev Neurol (Paris) 2012, 168:15-27.
21. Gamboa O.L., Tagliazucchi E., von Wegner F., et al. Working memory performance of early MS patients correlates inversely with modularity increases in resting state functional connectivity networks. Neuroimage 2014, 94:385-395.
22. Lafosse J.M., Mitchell S.M., Corboy J.R., et al. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc 2013, 19:995-1008.
23. Nagy H., Bencsik K., Rajda C., et al. The effects of reward and punishment contingencies on decision-making in multiple sclerosis. J Int Neuropsychol Soc 2006, 12:559-565.
24. Arnett P.A., Rao S.M., Grafman J., et al. Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology 1997, 11:535-544.
25. Foong J., Rozewicz L., Quaghebeur G., et al. Executive function in multiple sclerosis. The role of frontal lobe pathology. Brain 1997, 120(Pt 1):15-26.
26. Foong J., Rozewicz L., Davie C.A., et al. Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. J Neuropsychiatry Clin Neurosci 1999, 11:45-50.
27. Chiaravalloti N.D., DeLuca J. Assessing the behavioral consequences of multiple sclerosis: an application of the frontal systems behavior scale (FrSBe). Cogn Behav Neurol 2003, 16:54-67.
28. Hoffmann M., Cases L.B., Hoffmann B., et al. The impact of stroke on emotional intelligence. BMC Neurol 2010, 10:103.
29. Ghajarzadeh M., Owji M., Sahraian M.A., et al. Emotional intelligence (EI) of patients with multiple sclerosis (MS). Iran J Public Health 2014, 43:1550-1556.
30. Marvel C.L., Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am 2004, 27:19-36.
31. Farez M.F., Crivelli L., Leiguarda R., et al. Decision-making impairment in patients with multiple sclerosis: a case-control study. BMJ Open 2014, 4(7):e004918.
32. Ron M.A., Logsdail S.J. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med 1989, 19:887-895.
33. Heaton R.K., Nelson L.M., Thompson D.S., et al. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol 1985, 53:103-110.
34. Rosti-Otajärvi E., Hämäläinen P. Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis. Mult Scler 2013, 19(1):31-45.
35. Minden S.L., Orav J., Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987, 9:426-434.
36. Sadovnick A.D., Remick R.A., Allen J., et al. Depression and multiple sclerosis. Neurology 1996, 46:628-632.
37. Mrabet S., Ben Ali N., Kchaou M., et al. Depression in multiple sclerosis. Rev Neurol (Paris) 2014, 170:700-702.
38. Joffe R.T., Lippert G.P., Gray T.A., et al. Mood disorder and multiple sclerosis. Arch Neurol 1987, 44:376-378.
39. Jones K.H., Jones P.A., Middleton R.M., et al. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS Register. PLoS One 2014, 9(8):e104604.
40. Chwastiak L., Ehde D.M., Gibbons L.E., et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002, 159:1862-1872.
41. Azimian M., Shahvarughi-Farahani A., Rahgozar M., et al. Fatigue, depression, and physical impairment in multiple sclerosis. Iran J Neurol 2014, 13:105-107.
42. Lebrun C., Cohen M. Depression in multiple sclerosis. Rev Neurol (Paris) 2009, 165(Suppl 4):S156-S162.
43. Feinstein A. Multiple sclerosis and depression. Mult Scler 2011, 17:1276-1281.
44. Salehpoor G., Rezaei S., Hosseininezhad M. Quality of life in multiple sclerosis (MS) and role of fatigue, depression, anxiety, and stress: a bicenter study from north of Iran. Iran J Nurs Midwifery Res 2014, 19(6):593-599.
45. Chwastiak L.A., Ehde D.M. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007, 30:803-817.
46. Beiske A.G., Svensson E., Sandanger I., et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008, 15:239-245.
47. Wood B., van der Mei I.A., Ponsonby A.L., et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler 2013, 19:217-224.
48. Askari F., Ghajarzadeh M., Mohammadifar M., et al. Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Med Iran 2014, 52:889-892.
49. Korostil M., Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007, 13:67-72.
50. Zorzon M., de Masi R., Nasuelli D., et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 2001, 248:416-421.
51. Stathopoulou A., Christopoulos P., Soubasi E., et al. Personality characteristics and disorders in multiple sclerosis patients: assessment and treatment. Int Rev Psychiatry 2010, 22:43-54.
52. Ozura A., Erdberg P., Sega S. Personality characteristics of multiple sclerosis patients: a Rorschach investigation. Clin Neurol Neurosurg 2010, 112(7):629-632.
53. Bruce J.M., Lynch S.G. Personality traits in multiple sclerosis: association with mood and anxiety disorders. J Psychosom Res 2011, 70:479-485.
54. Gioia M.C., Cerasa A., Valentino P., et al. Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: an fMRI study. Brain Cogn 2009, 71(3):320-327.
55. Benedict R.H., Hussein S., Englert J., et al. Cortical atrophy and personality in multiple sclerosis. Neuropsychology 2008, 22:432-441.
56. Benedict R.H., Carone D.A., Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 2004, 14(3 Suppl):36S-45S.
57. Bruce J.M., Hancock L.M., Arnett P., et al. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010, 33:219-227.
58. Marrie R.A., Reingold S., Cohen J., et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 2015, 21:305-317.
59. Feinstein A., DeLuca J., Baune B.T., et al. Cognitive and neuropsychiatric disease manifestations in MS. Mult Scler Relat Disord 2013, 2:4-12.
60. Aggarwal A., Sharma D.D., Kumar R., et al. Acute psychosis as the initial presentation of MS: a case report. Int MS J 2011, 17:54-57.
61. Carrieri P.B., Montella S., Petracca M. Psychiatric onset of multiple sclerosis: description of two cases. J Neuropsychiatry Clin Neurosci 2011, 23(2):E6.
62. Feinstein A., du Boulay G., Ron M.A. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry 1992, 161:680-685.
63. Bombardier C.H., Blake K.D., Ehde D.M., et al. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler 2004, 10(1):35-40.
64. Turner A.P., Hawkins E.J., Haselkorn J.K., et al. Alcohol misuse and multiple sclerosis. Arch Phys Med Rehabil 2009, 90:842-848.
65. Massa J., O'Reilly E.J., Munger K.L., et al. Caffeine and alcohol intakes have no association with risk of multiple sclerosis. Mult Scler 2013, 19:53-58.
66. Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 2012, 21:1679-1699.
67. Patti F., Amato M.P., Bastianello S., COGIMUS Study Group, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010, 16:68-77.
68. Patti F., Amato M.P., Trojano M., COGIMUS Study Group, et al. Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). Qual Life Res 2012, 21:1111-1121.
69. Lacy M., Hauser M., Pliskin N., et al. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler 2013, 19(13):1765-1772.
70. Mokhber N., Azarpazhooh A., Orouji E., et al. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci 2014, 342:16-20.
71. LoPresti P. Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis. Neurochem Res 2015, 40:473-479.
72. Weinstein A., Schwid S.R., Schiffer R.B., et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999, 56:319-324.
73. Portaccio E., Stromillo M.L., Goretti B., et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis-a prospective, non-randomized pilot study. Eur J Neurol 2013, 20:986-990.
74. Iaffaldano P., Viterbo R.G., Paolicelli D., et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 2012, 7:e35843.
75. Wilken J., Kane R.L., Sullivan C.L., et al. Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab: the ENER-G Study. Int J MS Care 2013, 15:120-128.
76. Noetzli M., Eap C.B. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet 2013, 52:225-241.
77. Krupp L.B., Christodoulou C., Melville P., et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004, 63:1579-1585.
78. O'Carroll C.B., Woodruff B.K., Locke D.E., et al. Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic. Neurologist 2012, 18:51-54.
79. Krupp L.B., Christodoulou C., Melville P., et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011, 76:1500-1507.
80. He D., Zhang Y., Dong S., et al. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev 2013, (12). CD008876.
81. Mäurer M., Ortler S., Baier M., et al. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler 2013, 19:631-638.
82. Lovera J.F., Frohman E., Brown T.R., et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010, 16:715-723.
83. Johnson S.K., Diamond B.J., Rausch S., et al. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY) 2006, 2:19-24.
84. Lovera J., Bagert B., Smoot K., et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007, 13:376-385.
85. Lovera J.F., Kim E., Heriza E., et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology 2012, 79:1278-1284.
86. Hämäläinen P., Rosti-Otajärvi E. Is neuropsychological rehabilitation effective in multiple sclerosis?. Neurodegener Dis Manag 2014, 4:147-154.
87. Chiaravalloti N.D., Wylie G., Leavitt V., et al. Increased cerebral activation after behavioral treatment for memory deficits in MS. J Neurol 2012, 259:1337-1346.
88. Gich J., Freixanet J., García R., et al. A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis. Mult Scler 2015, [Epub ahead of print].
89. Rosti-Otajärvi E.M., Hämäläinen P.I. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 2014, (2). CD009131.
90. Skokou M., Soubasi E., Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012, 2012:427102.
91. Pérez L.P., González R.S., Lázaro E.B. Treatment of mood disorders in multiple sclerosis. Curr Treat Options Neurol 2015, 17:323.
92. Taler M., Gil-Ad I., Korob I., et al. The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation 2011, 18:117-122.
93. Ehde D.M., Kraft G.H., Chwastiak L., et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008, 30:40-48.
94. Shafey H. The effect of fluoxetine in depression associated with multiple sclerosis. Can J Psychiatry 1992, 37:147-148.
95. Sijens P.E., Mostert J.P., Irwan R., et al. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 2008, 164:274-282.
96. Mostert J.P., Admiraal-Behloul F., Hoogduin J.M., et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008, 79:1027-1031.
97. Browning W.N. Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine. Am J Psychiatry 1990, 147:1089.
98. Schiffer R.B., Wineman N.M. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990, 147:1493-1497.
99. Stip E., Daoust L. Valproate in the treatment of mood disorder due to multiple sclerosis. Can J Psychiatry 1995, 40:219-220.
100. Marazziti D., Cassano G.B. Valproic acid for panic disorder associated with multiple sclerosis. Am J Psychiatry 1996, 153:842-843.
101. Larcombe N.A., Wilson P.H. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatry 1984, 145:366-371.
102. Hind D., Cotter J., Thake A., et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry 2014, 14:5.
103. Beckner V., Howard I., Vella L., et al. Telephone-administered psychotherapy for depression in MS patients: moderating role of social support. J Behav Med 2010, 33:47-59.
104. Boeschoten R.E., Nieuwenhuis M.M., van Oppen P., et al. Feasibility and outcome of a web-based self-help intervention for depressive symptoms in patients with multiple sclerosis: a pilot study. J Neurol Sci 2012, 315(1-2):104-109.
105. Boeschoten R.E., Dekker J., Uitdehaag B.M., et al. Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial. BMC Psychiatry 2012, 12:137.
106. Krystal A.D., Coffey C.E. Neuropsychiatric considerations in the use of electroconvulsive therapy. J Neuropsychiatry Clin Neurosci 1997, 9(2):283-292.
107. Coffey C.E., Weiner R.D., McCall W.V., et al. Electroconvulsive therapy in multiple sclerosis: a magnetic resonance imaging study of the brain. Convuls Ther 1987, 3:137-144.
108. Mattingly G., Baker K., Zorumski C.F., et al. Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients. J Neuropsychiatry Clin Neurosci 1992, 4:145-151.
109. Taylor K.L., Hadgkiss E.J., Jelinek G.A., et al. Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry 2014, 14:327.
110. Raglio A., Attardo L., Gontero G., et al. Effects of music and music therapy on mood in neurological patients. World J Psychiatry 2015, 5:68-78.
111. Chong S.A., Ko S.M. Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiatry 1997, 42:90-91.
112. Sharma E., Rao N.P., Venkatasubramanian G., et al. Successful treatment of co-morbid schizophrenia and multiple sclerosis. Asian J Psychiatr 2010, 3:235-236.
113. Pontikes T.K., Dinwiddie S.H. Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia. J ECT 2010, 26:270-271.
114. Urban-Kowalczyk M., Rudecki T., Wróblewski D., et al. Electroconvulsive therapy in patient with psychotic depression and multiple sclerosis. Neurocase 2014, 20:452-455.
115. O'Toole O., Clardy S., Lin Quek A.M. Paraneoplastic and autoimmune encephalopathies. Semin Neurol 2013, 33:357-364.
116. Irani S.R., Bera K., Waters P., et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133(Pt 6):1655-1667.
117. Dalmau J., Tüzün E., Wu H.Y., et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
118. Armangue T., Petit-Pedrol M., Dalmau J. Autoimmune encephalitis in children. J Child Neurol 2012, 27:1460-1469.
119. Corsellis J.A., Goldberg G.J., Norton A.R. Limbic encephalitis and its association with carcinoma. Brain 1968, 91:481-496.
120. Graus F., Saiz A. Limbic encephalitis: a probably under-recognized syndrome. Neurologia 2005, 20:24-30.
121. Machado S., Pinto A.N., Irani S.R. What should you know about limbic encephalitis?. Arq Neuropsiquiatr 2012, 70:817-822.
122. Lancaster E., Martinez-Hernandez E., Titulaer M.J., et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011, 77:1698-1701.
123. Carr I. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet 1982, 1(8276):844-845.
124. Kirshner H.S. Hashimoto's encephalopathy: a brief review. Currneurolneurosci Rep 2014, 14(9):476.
125. Tamagno G., Federspil G., Murialdo G. Clinical and diagnostic aspects of encephalopathy associated with autoimmune thyroid disease (or Hashimoto's encephalopathy). Intern Emerg Med 2006, 1:15-23.
126. Hoffmann F., Reiter K., Kluger G., et al. Seizures, psychosis and coma: severe course of Hashimoto encephalopathy in a six-year-old girl. Neuropediatrics 2007, 38:197-199.